Effectiveness and safety analysis of switching to tenofovir alafenamide after entecavir or tenofovir treatment

被引：0
|
作者：
Liu, Xue [1 ]
Zhao, Zhihao [1 ]
Kong, Xianggen [2 ]
Cui, Shiyu [2 ]
Jiang, Xuemei [2 ]
机构：
[1] Shandong Univ, Jinan, Peoples R China
[2] Shandong Publ Hlth Clin Ctr, Jinan, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-415
引用
收藏
页码：S804 / S805
页数：2
相关论文
共 50 条
  • [1] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Shao-Ming Chiu
    Kuo-Chin Chang
    Tsung-Hui Hu
    Chao-Hung Hung
    Jing-Houng Wang
    Sheng-Nan Lu
    Chien-Hung Chen
    Digestive Diseases and Sciences, 2023, 68 : 665 - 675
  • [2] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Chiu, Shao-Ming
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Chen, Chien-Hung
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 665 - 675
  • [3] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE AFTER SWITCHING FROM ENTECAVIR IN PATIENTS WITH CHRONIC HEPATITIS B
    Hann, Hie-Won L.
    Park, Grace
    Bin Park, Kyong
    Juon, Hee-Soon
    HEPATOLOGY, 2021, 74 : 480A - 480A
  • [4] Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
    Wang, Fa-Da
    Zhou, Jing
    Li, Lan-Qing
    Li, Yu-Jing
    Wang, Meng -Lan
    Tao, Ya-Chao
    Zhang, Dong-Mei
    Wang, Yong-Hong
    Chen, En-Qiang
    ANNALS OF HEPATOLOGY, 2023, 28 (05)
  • [5] Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B
    Hagiwara, Satoru .
    Nishida, Naoshi
    Ida, Hiroshi
    Ueshima, Kazuomi
    Minami, Yasunori
    Takita, Masahiro
    Komeda, Yoriaki
    Kudo, Masatoshi
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (10) : 1804 - 1810
  • [6] Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
    Sinakos, Emmanouil
    Kachru, Nandita
    Tsoulas, Christos
    Jeyakumar, Sushanth
    Smith, Nathaniel J.
    Yehoshua, Alon
    Cholongitas, Evangelos
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (04) : e230090
  • [7] Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide-an interim analysis
    Cheng, Pin-Nan
    Liu, Chun-Jen
    Chen, Jyh-Jou
    Feng, I-Cher
    Kuo, Hsing-Tao
    Lee, Pei-Lun
    Yu, Ming-Lung
    Chiu, Yencheng
    Hung-Chih, Chiu
    Chien, Shih-Chieh
    Chen, Pei-Jer
    JOURNAL OF HEPATOLOGY, 2022, 77 : S863 - S864
  • [8] Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide
    Roade, Luisa
    Loglio, Alessandro
    Borghi, Marta
    Riveiro-Barciela, Mar
    Soffredini, Roberta
    Facchetti, Floriana
    di Paolo, Dhanai
    Tabernero, David
    Lunghi, Giovanna
    Esteban, Rafael
    Buti, Maria
    Lampertico, Pietro
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (10) : 1164 - 1169
  • [9] Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B
    Liu, Rui
    Qiao, Jin
    Zhang, Lin
    Dou, Zhihua
    MEDICINE, 2024, 103 (20) : E37953
  • [10] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?
    Squillace, N.
    Ricci, E.
    Menzaghi, B.
    Migliorino, G.
    De Socio, G.
    Passerini, S.
    Martinelli, C.
    Mameli, M.
    Maggi, P.
    Falasca, K.
    Cordier, L.
    Celesia, B.
    Salomoni, E.
    Di Biagio, A.
    Pellicano, G.
    Bonfanti, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345